ZLAB News and Press, Zai Lab Limited From 06/10/22

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy -- Potential best-in-class therapy for ROS1-positive metastatic NS...

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Novocure (NASDAQ: NVCR), a global oncology company working to extend surviv...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and ST. HELIER, Jersey, June 03, ...

Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy Results showed a significant exte...

The KWEB ETF has been battered significantly as investors left Chinese Internet stocks in a hurry since 2021. However, we could be in the late stage of the current malaise. Our price action analysis suggests that the worst in Chinese Internet stocks seems to have been priced in. KWEB'...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following i...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19...

Zai Lab reported its loss shrank 65% in the first quarter of the year while its revenues continued to rise. The company slashed its R&D costs by cutting licensing payments for existing drugs while spending more on finding new remedies. If Zai Lab manages to find the right cure...

The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q1 earnings call. For further details see: Zai Lab Limited 2022 Q1 - Results - Earnings Call Presentation